Podcast Pearls
The Evolving Role of TKIs in First-line Treatment of Advanced HCC

Summary slides for a podcast where Josep M. Llovet, MD, PhD, and Markus Peck-Radosavljevic, MD, MBA, discuss the evolving role of tyrosine kinase inhibitors in the first-line treatment of patients with advanced hepatocellular carcinoma.
Josep M. Llovet, MD
Univ. Prof. Dr. Markus Peck-Radosavljevic, MD, MBA
Format: Microsoft PowerPoint (.ppt)
File Size: 1.13 MB
Released: December 14, 2021

Acknowledgements

Supported by an educational grant from
Bayer HealthCare Pharmaceuticals Inc.

Related Content

Downloadable slideset with highlights from key gastrointestinal cancers as presented at 2022 ESMO World Congress on Gastrointestinal Cancer, from Clinical Care Options (CCO)

Released: August 16, 2022

Patient-reported outcomes from the HIMALAYA study of durvalumab with or without tremelimumab vs sorafenib in unresectable hepatocellular carcinoma, presented at ASCO 2022 and reported by Clinical Care Options (CCO)

Released: June 6, 2022

Experts highlight key studies being presented at the 2022 ASCO Annual Meeting in this commentary from Clinical Care Options (CCO)

Allison Betof Warner, MD, PhD John M. Burke, MD Shaji K. Kumar, MD Christopher H. Lieu, MD Stephen V. Liu, MD Joyce O'Shaughnessy, MD Zofia Piotrowska, MD, MHS Angeles Alvarez Secord, MD, MHSc Rachna Shroff, MD Hussein Tawbi, MD, PhD Eunice S. Wang, MD Released: June 1, 2022

Clinical Care Options (CCO): Experts review key data for gastric, rectal, liver, hepatobiliary tract, and pancreas cancers from the 2022 ASCO Gastrointestinal Cancers Symposium and the ASCO Plenary Series

Manish A. Shah, MD Rachna Shroff, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: April 20, 2022 Expired: April 19, 2023

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings